{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.9","upperLimit":"78.6","value":"66.7"},{"groupId":"OG001","lowerLimit":"10.7","upperLimit":"41.2","value":"23.5"},{"groupId":"OG002","lowerLimit":"11.8","upperLimit":"61.6","value":"33.3"},{"groupId":"OG003","lowerLimit":"13.9","upperLimit":"68.4","value":"38.5"},{"groupId":"OG004","lowerLimit":"32.8","upperLimit":"74.4","value":"54.2"},{"groupId":"OG005","lowerLimit":"8.6","upperLimit":"42.3","value":"22.2"},{"groupId":"OG006","lowerLimit":"46.0","upperLimit":"83.5","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"27"}],"units":"Participants"}],"description":"A DCR was defined as the proportion of participants with objective evidence of CR, PR, or stable disease (SD), except that there was no requirement for a confirmation of an SD, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. For Cohorts 1 to 6: DCR was based on IRC and for pooled Sub-cohort: DCR was based on investigator review.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Phase 1: Dose Expansion Cohort 1"},{"description":"Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Phase 1: Dose Expansion: Cohort 2"},{"description":"Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG002","title":"Phase 1: Dose Expansion: Cohort 3"},{"description":"Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG003","title":"Phase 1: Dose Expansion: Cohort 4"},{"description":"Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG004","title":"Phase 1: Dose Expansion: Cohort 5"},{"description":"Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG005","title":"Phase 1: Dose Expansion: Cohort 6"},{"description":"Participants with iCCA and other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG006","title":"Phase 1: Dose Expansion: Pooled Sub-cohort"}],"paramType":"NUMBER","populationDescription":"Efficacy population included all participants who had received at least 1 dose of TAS-120. Data was planned to be collected and analyzed on pooled population of participants who received 16 mg of TAS-120 in the sub-cohorts 1 and 2.","reportingStatus":"POSTED","timeFrame":"Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohort","title":"Phase 1: Dose Expansion: Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}